Company overview
SomaLogic provides advanced proteomics technology that measures approximately 7,000 proteins simultaneously from small biological samples, enabling biomarker discovery, diagnostics development, and drug discovery. The company's SomaScan Platform offers high specificity, sensitivity, and reproducibility, and is now part of Illumina following their acquisition. SomaLogic serves academic institutions, biopharmaceutical researchers, and clinical applications through its SomaSignal Tests for disease risk assessment and health monitoring.
SomaLogic is listed in the NovaPharmaNews Supplier Hub as a Life Science Reagents, Diagnostics & Testing partner serving United States & Americas. Core focus areas include proteomics technology, protein measurement, biomarker discovery, drug discovery, somascan platform.
Industry categories: Life Science Reagents, Diagnostics & Testing. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Structured facts
- Website
- https://somalogic.com/
- Categories
- Life Science Reagents, Diagnostics & Testing
- Markets served
- United States & Americas
- Keywords
- proteomics technology, protein measurement, biomarker discovery, drug discovery, somascan platform
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What is SomaLogic's core technology and what can it measure?
- SomaLogic's proprietary SomaScan Assay measures approximately 7,000 proteins simultaneously from a single 55-µl plasma or serum sample. It is the only technology capable of measuring broadly (high and low-abundance proteins), deeply (with high specificity and sensitivity), and rapidly (high throughput) in small sample volumes. The platform can measure up to 11,000 protein analytes through customizable panels.
- What applications does SomaLogic support for pharmaceutical R&D?
- SomaLogic's technology accelerates biomarker discovery, diagnostics development, drug discovery and development, and health management. The company has assembled the world's largest database of protein measurements from over 450,000 samples and uses machine learning and bioinformatics to generate quantitative risk assessments and disease insights. Researchers can use the platform to rapidly determine whether health interventions are working.
- What clinical products does SomaLogic offer?
- SomaLogic offers SomaSignal Tests for clinical use, which predict current health state and future disease risk from blood protein patterns. Available tests include Primary Cardiovascular Risk (4-year prediction for patients with no prior cardiovascular disease) and Residual Cardiovascular Risk (4-year prediction for patients 40+ with stable cardiovascular disease). Test results change in response to therapeutic and lifestyle interventions.
Related editorial coverage
- Drug Discovery USA 2026: What to Expect
- Lunai Bioworks and BrainStorm Therapeutics Launch AI Collaboration for Parkinson's and Rare Epilepsy
- Verge Rebrands AI Drug Discovery After Trial Setback
- Streamlined R&D at Novo Nordisk: Insights from Research Chief Petersen
- BBSW AI Solution Event: Daily Roundup
- BBSW AI Solution Event: Biotech Innovation in US
Explore lab tools and QA/QC resources for R&D teams.
